药学学报, 2022, 57(2): 265-270
引用本文:
余孝游, 蒋建东*, 王璐璐*. 天然来源化合物治疗非酒精性脂肪性肝病研究进展[J]. 药学学报, 2022, 57(2): 265-270.
YU Xiao-you, JIANG Jian-dong*, WANG Lu-lu*. Research progress of natural-derived compounds in the treatment of non-alcoholic fatty liver disease[J]. Acta Pharmaceutica Sinica, 2022, 57(2): 265-270.

天然来源化合物治疗非酒精性脂肪性肝病研究进展
余孝游, 蒋建东*, 王璐璐*
中国医学科学院、北京协和医学院药物研究所, 北京 100050
摘要:
非酒精性脂肪性肝病(NAFLD)是最常见的慢性肝脏疾病,其在世界范围的患病率逐年上升,严重威胁着公众生命健康。NAFLD发病机制复杂,目前尚无特效治疗药物。天然来源化合物具有多靶点、多机制的特点,可以通过调控疾病的多个环节提高疗效,降低毒副作用,经常是治疗复杂性疾病的理想药物,对改善NAFLD具有独特优势。但许多化合物口服吸收差、生物利用度低,单药疗效不显著,进一步的药物开发及临床应用具有挑战。本文综述了近年来天然来源化合物防治NAFLD研究的进展,分析存在的问题并探讨了改进的策略,以期为相关研究提供参考。
关键词:    非酒精性脂肪性肝病      天然来源化合物      药物递送系统      纳米制剂     
Research progress of natural-derived compounds in the treatment of non-alcoholic fatty liver disease
YU Xiao-you, JIANG Jian-dong*, WANG Lu-lu*
Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
Abstract:
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease. The prevalence of NAFLD is increasing year by year in the world, which seriously threaten the public health. The pathogenesis of NAFLD is complex, and there is no specific treatment for NAFLD. Natural-derived compounds have the characteristics of multi-target and multi-mechanism, which can improve the curative effect and reduce the toxic and side effects by regulating multiple factors of the disease. They are ideal drugs for treating complex diseases and have unique advantages in improving NAFLD. However, low intestinal absorption, poor bioavailability, and single medicine efficiency limit the utilization of many compounds, and further drug development and clinical application are challenging. This paper reviews the research progress of natural-derived compounds in the prevention and treatment of NAFLD in recent years, analyzes the existing problems, and discusses the improvement strategies, so as to provide reference for related research.
Key words:    non-alcoholic fatty liver disease    natural-derived compound    drug delivery system    nanoformulation   
收稿日期: 2021-06-10
DOI: 10.16438/j.0513-4870.2021-0862
通讯作者: 蒋建东,Tel:86-10-63017906,E-mail:jiang.jdong@163.com;王璐璐,Tel:13621284066,E-mail:wanglulu@imm.ac.cn
Email: jiang.jdong@163.comwanglulu@imm.ac.cn
相关功能
PDF(655KB) Free
打印本文
0
作者相关文章
余孝游  在本刊中的所有文章
蒋建东*  在本刊中的所有文章
王璐璐*  在本刊中的所有文章

参考文献:
[1] Gerges SH, Wahdan SA, Elsherbiny DA, et al. Non-alcoholic fatty liver disease:an overview of risk factors, pathophysiological mechanisms, diagnostic procedures, and therapeutic interventions[J]. Life Sci, 2021, 271:119220.
[2] Nasr P, Iredahl F, Dahlstrom N, et al. Evaluating the prevalence and severity of NAFLD in primary care:the EPSONIP study protocol[J]. BMC Gastroenterol, 2021, 21:180.
[3] Zhou F, Zhou J, Wang W, et al. Unexpected rapid increase in the burden of NAFLD in China from 2008 to 2018:a systematic review and meta-analysis[J]. Hepatology, 2019, 70:1119-1133.
[4] European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease[J]. Diabetologia, 2016, 59:1121-1140.
[5] Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease:practice guidance from the American Association for the Study of Liver Diseases[J]. Hepatology, 2018, 67:328-357.
[6] National Workshop on Fatty Liver and Alcoholic Liver Disease, Chinese Society of Hepatology, Chinese Medical Association; Fatty Liver Disease Expert Committee, Chinese Medical Doctor Association. Guidelines of prevention and treatment for nonalcoholic fatty liver disease:a 2018 update[J]. Chin J Hepatol (中华肝脏病杂志), 2018, 26:195-203.
[7] Kung J, Henry RR. Thiazolidinedione safety[J]. Expert Opin Drug Saf, 2012, 11:565-579.
[8] Vuppalanchi R, Noureddin M, Alkhouri N, et al. Therapeutic pipeline in nonalcoholic steatohepatitis[J]. Nat Rev Gastroenterol Hepatol, 2021, 18:373-392.
[9] Zhou H, Ma C, Wang C, et al. Research progress in use of traditional Chinese medicine monomer for treatment of non-alcoholic fatty liver disease[J]. Eur J Pharmacol, 2021, 898:173976.
[10] Sun R, Xu D, Wei Q, et al. Silybin ameliorates hepatic lipid accumulation and modulates global metabolism in an NAFLD mouse model[J]. Biomed Pharmacother, 2020, 123:109721.
[11] Yang L, Liu Q, Zhang H, et al. Silibinin improves nonalcoholic fatty liver by regulating the expression of miR122:an in vitro and in vivo study[J]. Mol Med Rep, 2021, 23:335.
[12] Yan T, Yan N, Wang P, et al. Herbal drug discovery for the treatment of nonalcoholic fatty liver disease[J]. Acta Pharm Sin B, 2020, 10:3-18.
[13] Anushiravani A, Haddadi N, Pourfarmanbar M, et al. Treatment options for nonalcoholic fatty liver disease:a double-blinded randomized placebo-controlled trial[J]. Eur J Gastroenterol Hepatol, 2019, 31:613-617.
[14] Navarro VJ, Belle SH, D'amato M, et al. Silymarin in non-cirrhotics with non-alcoholic steatohepatitis:a randomized, double-blind, placebo controlled trial[J]. PLoS One, 2019, 14:e0221683.
[15] Sun Y, Peng ML. Recent advances in curcumin and its derivatives for treatment of liver diseases[J]. Acta Pharm Sin (药学学报), 2014, 49:1483-1490.
[16] Feng W, Wang H, Zhang P, et al. Modulation of gut microbiota contributes to curcumin-mediated attenuation of hepatic steatosis in rats[J]. Biochim Biophys Acta Gen Subj, 2017, 1861:1801-1812.
[17] Saadati S, Sadeghi A, Mansour A, et al. Curcumin and inflammation in non-alcoholic fatty liver disease:a randomized, placebo controlled clinical trial[J]. BMC Gastroenterol, 2019, 19:133.
[18] Wei Z, Liu N, Tantai X, et al. The effects of curcumin on the metabolic parameters of non-alcoholic fatty liver disease:a meta-analysis of randomized controlled trials[J]. Hepatol Int, 2019, 13:302-313.
[19] Zhao T, Mao L, Yu Z, et al. Therapeutic potential of bicyclol in liver diseases:lessons from a synthetic drug based on herbal derivative in traditional Chinese medicine[J]. Int Immunopharmacol, 2021, 91:107308.
[20] Zhao TM, Wang Y, Deng Y, et al. Bicyclol attenuates acute liver injury by activating autophagy, anti-oxidative and anti-inflammatory capabilities in mice[J]. Front Pharmacol, 2020, 11:463.
[21] Yao XM, Li Y, Li HW, et al. Bicyclol attenuates tetracycline-induced fatty liver associated with inhibition of hepatic ER stress and apoptosis in mice[J]. Can J Physiol Pharmacol, 2016, 94:1-8.
[22] Wang YN, Zhang XL, Yin Z, et al. Experimental study of bicyclol for type 2 diabetic treatment using KKAy mice[J]. Acta Pharm Sin (药学学报), 2019, 54:1041-1047.
[23] Han Y, Shi JP, Ma AL, et al. Randomized, vitamin E-controlled trial of bicyclol plus metformin in non-alcoholic fatty liver disease patients with impaired fasting glucose[J]. Clin Drug Investig, 2014, 34:1-7.
[24] Li H, Liu NN, Peng ZG. Effect of bicyclol on blood biomarkers of NAFLD:a systematic review and meta-analysis[J]. BMJ Open, 2020, 10:e039700.
[25] Tian Y, Ma J, Wang W, et al. Resveratrol supplement inhibited the NF-κB inflammation pathway through activating AMPKα-SIRT1 pathway in mice with fatty liver[J]. Mol Cell Biochem, 2016, 422:75-84.
[26] Charytoniuk T, Drygalski K, Konstantynowicz-Nowicka K, et al. Alternative treatment methods attenuate the development of NAFLD:a review of resveratrol molecular mechanisms and clinical trials[J]. Nutrition, 2017, 34:108-117.
[27] Chaplin A, Carpene C, Mercader J. Resveratrol, metabolic syndrome, and gut microbiota[J]. Nutrients, 2018, 10:1651.
[28] Wang P, Wang J, Li D, et al. Targeting the gut microbiota with resveratrol:a demonstration of novel evidence for the management of hepatic steatosis[J]. J Nutr Biochem, 2020, 81:108363.
[29] Chen S, Zhao X, Ran L, et al. Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease:a randomized controlled trial[J]. Dig Liver Dis, 2015, 47:226-232.
[30] Jakubczyk K, Skonieczna-Zydecka K, Kaldunska J, et al. Effects of resveratrol supplementation in patients with non-alcoholic fatty liver disease-a meta-analysis[J]. Nutrients, 2020, 12:2435.
[31] Yan T, Wang H, Cao L, et al. Glycyrrhizin alleviates nonalcoholic steatohepatitis via modulating bile acids and meta-inflammation[J]. Drug Metab Dispos, 2018, 46:1310-1319.
[32] Wang C, Duan X, Sun X, et al. Protective effects of glycyrrhizic acid from edible botanical glycyrrhiza glabra against non-alcoholic steatohepatitis in mice[J]. Food Funct, 2016, 7:3716-3723.
[33] Li Y, Liu T, Yan C, et al. Diammonium glycyrrhizinate protects against nonalcoholic fatty liver disease in mice through modulation of gut microbiota and restoration of intestinal barrier[J]. Mol Pharm, 2018, 15:3860-3870.
[34] Sun X, Duan X, Wang C, et al. Protective effects of glycyrrhizic acid against non-alcoholic fatty liver disease in mice[J]. Eur J Pharmacol, 2017, 806:75-82.
[35] Sun X, Zhang L, Wei W, et al. Systematic evaluation and meta analysis on nonalcoholic steatohepatitis treated with glycyrrhizin[J]. Chin J Surg Integr Tradit West Med (世界中西医结合杂志), 2015, 10:265-271.
[36] Zuo X, Luo JQ, Jiang XH, et al. The anti-atherosclerotic effect and mechanism study of berberine in hyperlipidemic ApoE-/- mice[J]. Acta Pharm Sin (药学学报), 2019, 54:104-110.
[37] Ma XL, Jiang W, Fan WM, et al. Berberine ameliorates dexamethasone-induced metabolic disorder in C57 mice[J]. Acta Pham Sin (药学学报), 2020, 55:2636-2641.
[38] Yao J, Kong W, Jiang J. Learning from berberine:treating chronic diseases through multiple targets[J]. Sci China Life Sci, 2015, 58:854-859.
[39] Wang Y, Jiang JD. A new research mode of drug PK-PD mediated by the gut microbiota:insights into the pharmacokinetics of berberine[J]. Acta Pharm Sin (药学学报), 2018, 53:659-666.
[40] Zhu L, Zhang D, Zhu H, et al. Berberine treatment increases Akkermansia in the gut and improves high-fat diet-induced atherosclerosis in Apoe-/- mice[J]. Atherosclerosis, 2018, 268:117-126.
[41] Zhang Z, Li B, Meng X, et al. Berberine prevents progression from hepatic steatosis to steatohepatitis and fibrosis by reducing endoplasmic reticulum stress[J]. Sci Rep, 2016, 6:20848.
[42] Bai RM, Zheng BB, Zhang RD, et al. Effects of berberine on insulin resistance and serum adiponectin of nonalcoholic fatty liver patients[J]. Pract Geriatr (实用老年医学), 2011, 25:423-426.
[43] Xie XM, Meng XJ, Zhou XJ, et al. The effency of berberine in newly diagnosed type 2 diabetes mellitus with nonalcoholic fatty liver disease patients and the influence of blood rheology[J]. China J Chin Mater Med (中国中药杂志), 2011, 36:3032-3035.
[44] Yan HM, Xia MF, Wang Y, et al. Efficacy of berberine in patients with non-alcoholic fatty liver disease[J]. PLoS One, 2015, 10:e0134172.
[45] Chang X, Wang Z, Zhang J, et al. Lipid profiling of the therapeutic effects of berberine in patients with nonalcoholic fatty liver disease[J]. J Transl Med, 2016, 14:266.
[46] Battu SK, Repka MA, Maddineni S, et al. Physicochemical characterization of berberine chloride:a perspective in the development of a solution dosage form for oral delivery[J]. AAPS PharmSciTech, 2010, 11:1466-1475.
[47] Meng ZJ, Zhang M, Wei SN, et al. Amorphous solid dispersion of berberine with absorption enhancer demonstrates a remarkable hypoglycemic effect via improving its bioavailability[J]. Int J Pharm, 2014, 467:50-59.
[48] Maradana MR, Yekollu SK, Zeng B, et al. Immunomodulatory liposomes targeting liver macrophages arrest progression of nonalcoholic steatohepatitis[J]. Metabolism, 2018, 78:80-94.
[49] Yang KW, Li XR, Yang ZL, et al. Novel polyion complex micelles for liver-targeted delivery of diammonium glycyrrhizinate:in vitro and in vivo characterization[J]. J Biomed Mater Res Part A, 2009, 88:140-148.
[50] Teng W, Zhao L, Yang S, et al. The hepatic-targeted, resveratrol loaded nanoparticles for relief of high fat diet-induced nonalcoholic fatty liver disease[J]. J Control Release, 2019, 307:139-149.
[51] Xue M, Zhang L, Yang MX, et al. Berberine-loaded solid lipid nanoparticles are concentrated in the liver and ameliorate hepato-steatosis in db/db mice[J]. Int J Nanomedicine, 2015, 10:5049-5057.
[52] Guo HH, Ma C, Zheng WS, et al. Dual-stimuli-responsive gut microbiota-targeting berberine-CS/PT-NPs improved metabolic status in obese hamsters[J]. Adv Funct Mater, 2019, 29:16.
[53] Chen CH, Chen CJ, Elzoghby AO, et al. Self-assembly and directed assembly of lipid nanocarriers for prevention of liver fibrosis in obese rats:a comparison with the therapy of bariatric surgery[J]. Nanomedicine (Lond), 2018, 13:1551-1566.